Keywords: Takeda, FDA, type 2 diabetes, Actos

Takeda gets FDA Complete Response letter for fixed-dose alogliptin and Actos for type 2 diabetes

Article | 07 September 2009

Japan’s leading drugmaker Takeda says that its wholly-owned US subsidiary, Takeda Global Research & Development Center, has received a complete ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Actos

Pioglitazone

Go to drug listing